Enlight Renewable Energy posted a 54% increase in total revenues and income to $200 million for Q1 2026, driven by higher electricity sales and tax benefits from US projects. Adjusted EBITDA rose 17% to $154 million, with a 58% increase excluding gains from asset sales. The company expanded its renewable energy portfolio to 41.2 FGW, focusing on energy storage and US projects, and reaffirmed 2026 guidance of 32% revenue growth and 27% EBITDA growth. Strong operational cash flow and significant project financing support Enlight's growth amid global market challenges.
AGC Biologics has signed a multi-year commercial manufacturing agreement with a major pharmaceutical company for its new Yokohama facility, locking in half of the mammalian cell production capacity. The deal, worth hundreds of millions of dollars, co...
AGC Biologics has signed a multi-year commercial manufacturing contract valued at hundreds of millions of dollars with a major biopharma company for its new Yokohama facility. The contract covers production of five biopharmaceutical programs, securin...
AGC Biologics has secured a long-term commercial manufacturing contract with a global biopharma company for its new Yokohama facility, expected to generate hundreds of millions of dollars. The contract covers production of five biopharmaceutical prod...
Seagate Technology reported strong Q4 2026 results, beating earnings per share estimates with $5.71 and revenue of $3.63 billion, driven by high demand for data storage from the AI sector. The company showed solid financial health with a low debt-to-...
Replimune Group's stock fell sharply by 38.01% following FDA briefing documents that deemed its skin cancer drug trial data "not interpretable," signaling a major regulatory setback. Other companies like Travelzoo and Amkor Technology also saw signif...
